About Our Lab
About Our Lab
2022
-
Development of a Fully Automated Desktop Analyzer and Ultrahigh Sensitivity Digital Immunoassay for SARS-CoV-2 Nucleocapsid Antigen Detection.
Chiba R, Miyakawa K, Aoki K, Morikawa TJ, Moriizumi Y, Degawa T, Arai Y, Segawa O, Tanaka K, Tajima H, Arai S, Yoshinaga H, Tsukada R, Tani A, Fuji H, Sato A, Ishii Y, Tateda K, Ryo A, Yoshimura T. Biomedicines. 2022 Sep 15;10(9):2291.
-
Molecular Evolution of the Pseudomonas aeruginosa DNA Gyrase gyrA Gene.
Sada M, Kimura H, Nagasawa N, Akagawa M, Okayama K, Shirai T, Sunagawa S, Kimura R, Saraya T, Ishii H, Kurai D, Tsugawa T, Nishina A, Tomita H, Okodo M, Hirai S, Ryo A, Ishioka T, Murakami K. Microorganisms. 2022 Aug 17;10(8):1660.
-
Enhancement of humoral and cellular immunity against SARS-CoV-2 by a third dose of BNT162b2 vaccine in Japanese healthcare workers.
Miyakawa K, Kato H, Ohtake N, Stanleyraj Jeremiah S, Ryo A. J Infect Dis. 2022 Aug 18:jiac344.
-
Characterization and Utilization of Disulfide-Bonded SARS-CoV-2 Receptor Binding Domain of Spike Protein Synthesized by Wheat Germ Cell-Free Production System.
Yamaoka Y, Jeremiah SS, Funabashi R, Miyakawa K, Morita T, Mihana Y, Kato H, Ryo A. Viruses. 2022 Jul 1;14(7):1461.
-
Development of Parallel Reaction Monitoring Mass Spectrometry Assay for the Detection of Human Norovirus Major Capsid Protein.
Kimura Y, Shin J, Nakai Y, Takahashi M, Ino Y, Akiyama T, Goto K, Nagata N, Yamaoka Y, Miyakawa K, Kimura H, Ryo A. Viruses. 2022 Jun 28;14(7):1416.
-
A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron.
Maeda R, Fujita J, Konishi Y, Kazuma Y, Yamazaki H, Anzai I, Watanabe T, Yamaguchi K, Kasai K, Nagata K, Yamaoka Y, Miyakawa K, Ryo A, Shirakawa K, Sato K, Makino F, Matsuura Y, Inoue T, Imura A, Namba K, Takaori-Kondo A. Commun Biol. 2022 Jul 6;5(1):669.
-
Antimicrobial strategy for targeted elimination of different microbes, including bacterial, fungal and viral pathogens.
Mitsunaga M, Ito K, Nishimura T, Miyata H, Miyakawa K, Morita T, Ryo A, Kobayashi H, Mizunoe Y, Iwase T. Commun Biol. 2022 Jul 4;5(1):647.
-
Inhibition of nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy.
Murai K, Kodama T, Hikita H, Shimoda A, Fukuoka M, Fukutomi K, Shigeno S, Shiode Y, Motooka D, Higuchi Y, Miyakawa K, Suemizu H, Ryo A, Tahata Y, Makino Y, Yamada R, Sakamori R, Tatsumi T, Takehara T. Hepatol Commun. 2022 May 24. doi: 10.1002/hep4.2014. Epub ahead of print. PMID: 35608131.
-
An autopsy case of COVID-19-like acute respiratory distress syndrome after mRNA-1273 SARS-CoV-2 vaccination.
Yoshimura Y, Sasaki H, Miyata N, Miyazaki K, Okudela K, Tateishi Y, Hayashi H, Kawana-Tachikawa A, Iwashita H, Maeda K, Ihama Y, Hatayama Y, Ryo A, Tachikawa N. Int J Infect Dis. 2022 Apr 29:S1201-9712(22)00257-0.
-
Reduced replication efficacy of SARS-CoV-2 Omicron variant in "mini-gut" organoids.
Miyakawa K, Machida M, Kawasaki T, Nishi M, Akutsu H, Ryo A. Gastroenterology. 2022 Apr 29:S0016-5085(22)00456-5.
-
Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology.
Jeremiah SS, Miyakawa K, Ryo A. J Mol Cell Biol. 2022 Apr 13:mjac023. doi: 10.1093/jmcb/mjac023. Epub ahead of print. PMID: 35416249.
-
Crosstalk between the innate immune system and selective autophagy in hepatitis B virus infection.
Miyakawa K, Jeremiah SS, Ogawa M, Nishi M, Ohnishi M, Ryo A. Autophagy. 2022 Apr 5:1-2. doi: 10.1080/15548627.2022.2059747. Epub ahead of print. PMID: 35380913.
-
Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination.
Kato H, Miyakawa K, Ohtake N, Yamaoka Y, Yajima S, Yamazaki E, Shimada T,Goto A, Nakajima H, Ryo A.Vaccine. 2022 Mar 29:S0264-410X(22)00369-3
. -
Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2.
Koyama T, Miyakawa K, Tokumasu R, S Jeremiah S, Kudo M, Ryo A. Future Microbiol. 2022 Apr;17:417-424.
-
HSP90 inhibition overcomes resistance to molecular targeted therapy in BRAFV600E mutant high-grade glioma.
Sasame J, Ikegaya N, Kawazu M, Natsumeda M, Hayashi T, Isoda M, Satomi K,Tomiyama A, Oshima A, Honma H, Miyake Y, Takabayashi K, Nakamura T, Ueno T,Matsushita Y, Iwashita H, Kanemaru Y, Murata H, Ryo A, Terashima K, Yamanaka S,Fujii Y, Mano H, Komori T, Ichimura K, Cahill DP, Wakimoto H, Yamamoto T,Tateishi K. Clin Cancer Res. 2022 Mar 28:clincanres.3622.2021.
-
Molecular and Epidemiological Characterization of Emerging Immune-Escape Variants of SARS-CoV-2.
Miyakawa K, Jeremiah SS, Yamaoka Y, Koyama T, Tokumasu R, Kudo M, Kato H, RyoA. Front Med (Lausanne). 2022 Feb 10;9:811004.
-
Phosphopeptide enrichment using Phos-tag technology reveals functional phosphorylation of the nucleocapsid protein of SARS-CoV-2.
Ino Y, Nishi M, Yamaoka Y, Miyakawa K, Jeremiah SS, Osada M, Kimura Y, Ryo A. J Proteomics. 2022 Jan 29;255:104501.
-
Galectin-9 restricts hepatitis B virus replication via p62/SQSTM1-mediated selective autophagy of viral core proteins.
Miyakawa K, Nishi M, Ogawa M, Matsunaga S, Sugiyama M, Nishitsuji H, Kimura H, Ohnishi M, Watashi K, Shimotohno K, Wakita T, Ryo A. Nat Commun. 2022 Jan 27;13(1):531.
-
Establishment of monoclonal antibodies broadly neutralize infection of hepatitis B virus.
Zhang H, Itoh Y, Suzuki T, Ihara KI, Tanaka T, Haga S, Enatsu H, Yumiya M, Kimura M, Takada A, Itoh D, Shibazaki Y, Nakao S, Yoshio S, Miyakawa K, Miyamoto Y, Sasaki H, Kajita T, Sugiyama M, Mizokami M, Tachibana T, Ryo A, Moriishi K, Miyoshi E, Kanto T, Okamoto T, Matsuura Y. Microbiol Immunol. 2022 Jan 27. doi: 10.1111/1348-0421.12964. Epub ahead of print. PMID: 35084739.